Matched Phase II clinical trial
A matched Phase II clinical trial is a single-arm or small-controlled early-efficacy study in which treated patients are paired with matched controls — drawn from historical databases, registries, or concurrent external cohorts — on key prognostic variables such as age, disease stage, and performance status. This design allows preliminary efficacy assessment without a concurrent randomized arm, trading randomization for feasibility while partially controlling for confounding through the matching process.
Allikakirje
Tsiteeringud kopeeritud meetodi allikakirjest sõna-sõnalt. Nendest ei saa järeldada väidete tasemel kinnitust.
- Gehan, E. A. (1961). The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases, 13(4), 346–353. · DOI 10.1016/0021-9681(61)90060-1
- Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10(1), 1–10. · DOI 10.1016/0197-2456(89)90015-9
Kureeritud väited
Väited on salvestatud tõendite registrisse, igal oma hinnanguga.
See vaade ei loo väite hinnangut, kui registris seda pole.
Seotud meetodid
Genereeritud meetodigraafist ja kuvatud masina soovitatud seostena – väiteid ei järeldata.